Use of the JL1 epitope, which encompasses the nonglycosylation site of CD43, as a marker of immature/neoplastic langerhans cells

American Journal of Surgical Pathology

Volumn 36, Issue 8, 2012, Pages 1150-1157

  Park, Hyo Jin ^a,b   Jeon, Yoon Kyung ^b   Lee, An Hi ^c   Oh, Young Ha ^d   Park, Seong Hoe ^b   Jung, Kyeong Cheon ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Catholic Kwandong University International St Mary s Hospital   (South Korea)

^d Hanyang University College of Medicine   (South Korea)

Author keywords

histiocytic disorder; JL1; Langerhans cell histiocytosis; langerin

Indexed keywords

BIOLOGICAL MARKER; DIAGNOSTIC AGENT; EPITOPE; JL1 ANTIGEN; LEUKOSIALIN; MONOCLONAL ANTIBODY; T LYMPHOCYTE ANTIGEN;

ADOLESCENT; ADULT; ANTIBODY SPECIFICITY; ARTICLE; CELL DIFFERENTIATION; CHILD; FEMALE; HISTIOCYTOSIS X; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; LANGERHANS CELL; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD43; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CHILD; CHILD, PRESCHOOL; EPITOPES; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LANGERHANS CELLS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84863849310     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31825b9914     Document Type: Article

References (45)

1. Valladeau J, Dezutter-Dambuyant C, Saeland S. Langerin/CD207 sheds light on formation of birbeck granules and their possible function in Langerhans cells. Immunol Res. 2003;28:93-107. (Pubitemid 37465160)
2. Valladeau J, Ravel O, Dezutter-Dambuyant C, et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity. 2000;12:71-81. (Pubitemid 30069216)
3. Broadbent V, Egeler RM, Nesbit ME Jr. Langerhans cell histiocytosis-clinical and epidemiological aspects. Br J Cancer Suppl. 1994;23:S11-S16. (Pubitemid 24275532)
4. Chikwava K, Jaffe R. Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatr Dev Pathol. 2004;7:607-614.
5. Willman CL, Busque L, Griffith BB, et al. Langerhans'-cell histiocytosis (histiocytosis X)-a clonal proliferative disease. N Engl J Med. 1994;331:154-160. (Pubitemid 24209565)
6. Yu RC, Chu C, Buluwela L, et al. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet. 1994;343:767-768.
7. Betts DR, Leibundgut KE, Feldges A, et al. Cytogenetic abnormalities in Langerhans cell histiocytosis. Br J Cancer. 1998;77:552-555. (Pubitemid 28059460)
8. Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am J Surg Pathol. 2008;32:615-619. (Pubitemid 351458304)
9. Bank MI, Rengtved P, Carstensen H, et al. p53 expression in biopsies from children with Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2002;24:733-736. (Pubitemid 35448738)
10. Schouten B, Egeler RM, Leenen PJ, et al. Expression of cell cyclerelated gene products in Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2002;24:727-732. (Pubitemid 35448737)
11. Weintraub M, Bhatia KG, Chandra RS, et al. p53 expression in Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 1998;20: 12-17. (Pubitemid 28119750)
12. Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med. 2007;4:e253.
13. Demedts IK, Brusselle GG, Vermaelen KY, et al. Identification and characterization of human pulmonary dendritic cells. Am J Respir Cell Mol Biol. 2005;32:177-184. (Pubitemid 40387643)
14. Geissmann F, Dieu-Nosjean MC, Dezutter C, et al. Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med. 2002;196:417-430.
15. Seguier S, Bodineau A, Godeau G, et al. Langerin+ versus CD1a+ Langerhans cells in human gingival tissue: a comparative and quantitative immunohistochemical study. Arch Oral Biol. 2003;48: 255-262. (Pubitemid 36499877)
16. Park SH, Bae YM, Kwon HJ, et al. JL1, a novel differentiation antigen of human cortical thymocyte. J Exp Med. 1993;178: 1447-1451.
17. Kim TJ, Park SH. Immunotherapeutic potential of JL1, a thymocyte surface protein, for leukemia. J Korean Med Sci. 1998;13: 455-458. (Pubitemid 128686233)
18. Park WS, Bae YM, Chung DH, et al. A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias. Leukemia. 1998;12:1583-1590. (Pubitemid 28470443)
19. Jeon YK, Min HS, Lee YJ, et al. Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia. Cancer Immunol Immunother. 2011;60:1697-1706.
20. Fukuda M. Leukosialin, a major O-glycan-containing sialoglycoprotein defining leukocyte differentiation and malignancy. Glycobiology. 1991;1:347-356.
21. Remold-O'Donnell E, Zimmerman C, Kenney D, et al. Expression on blood cells of sialophorin, the surface glycoprotein that is defective in Wiskott-Aldrich syndrome. Blood. 1987;70:104-109. (Pubitemid 17111248)
22. Jones AT, Federsppiel B, Ellies LG, et al. Characterization of the activation-associated isoform of CD43 on murine T lymphocytes. J Immunol. 1994;153:3426-3439. (Pubitemid 24313845)
23. Park WS, Chae JS, Jung KC, et al. Production and the characterization of monoclonal antibody against CD43, K06. Tissue Antigens. 2004;63:46-53. (Pubitemid 38130442)
24. Shiota J, Nishimura H, Okamoto H, et al. A unique murine CD43 epitope Lp-3: distinct distribution from another CD43 epitope S7. Cell Immunol. 1994;155:402-413. (Pubitemid 24199132)
25. Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol. 1997;29:157-166.
26. Ginhoux F, Tacke F, Angeli V, et al. Langerhans cells arise from monocytes in vivo. Nat Immunol. 2006;7:265-273.
27. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol. 2008;8:935-947.
28. Dubrac S, Schmuth M, Ebner S. Atopic dermatitis: the role of Langerhans cells in disease pathogenesis. Immunol Cell Biol. 2010; 88:400-409.
29. Szakal AK, Kapasi ZF, Haley ST, et al. A theory of follicular dendritic cell origin. Curr Top Microbiol Immunol. 1995;201:1-13.
30. Degar BA, Rollins BJ. Langerhans cell histiocytosis: malignancy or inflammatory disorder doing a great job of imitating one? Dis Model Mech. 2009;2:436-439.
31. da Costa CE, Szuhai K, van Eijk R, et al. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer. 2009;48:239-249.
32. Emile JF, Fraitag S, Leborgne M, et al. Langerhans' cell histiocytosis cells are activated Langerhans' cells. J Pathol. 1994;174:71-76. (Pubitemid 24318449)
33. Fleming MD, Pinkus JL, Fournier MV, et al. Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis. Blood. 2003; 101:2473-2475. (Pubitemid 36857600)
34. Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood. 2001;97:1241-1248. (Pubitemid 32183745)
35. Yousem SA, Colby TV, Chen YY, et al. Pulmonary Langerhans' cell histiocytosis: molecular analysis of clonality. Am J Surg Pathol. 2001;25:630-636. (Pubitemid 32423361)
36. Dacic S, Trusky C, Bakker A, et al. Genotypic analysis of pulmonary Langerhans cell histiocytosis. Hum Pathol. 2003;34: 1345-1349. (Pubitemid 38018150)
37. Carlsson SR, Fukuda M. Isolation and characterization of leukosialin, a major sialoglycoprotein on human leukocytes. J Biol Chem. 1986;261:12779-12786. (Pubitemid 17204241)
38. Shin YK, Choi EY, Kim SH, et al. Expression of leukemiaassociated antigen, JL1, in bone marrow and thymus. Am J Pathol. 2001;158:1473-1480.
39. Edelweiss M, Medeiros LJ, Suster S, et al. Lymph node involvement by Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical study of 20 cases. Hum Pathol. 2007;38:1463-1469. (Pubitemid 47418970)
40. Clausen BE, Kel JM. Langerhans cells: critical regulators of skin immunity? Immunol Cell Biol. 2010;88:351-360.
41. Kripke ML, Munn CG, Jeevan A, et al. Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J Immunol. 1990;145:2833-2838. (Pubitemid 20382549)
42. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:327-338. (Pubitemid 28175883)
43. Abla O, Egeler RM, Weitzman S. Langerhans cell histiocytosis: current concepts and treatments. Cancer Treat Rev. 2010;36: 354-359.
44. Shin YK, Choi YL, Choi EY, et al. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications. Cancer Immunol Immunother. 2003;52:506-512. (Pubitemid 36963212)
45. Suh W, Chung JK, Park SH, et al. Anti-JL1 antibody-conjugated poly (L-lysine) for targeted gene delivery to leukemia T cells. J Control Release. 2001;72:171-178. (Pubitemid 32522355)